Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 231

1.

Short and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses.

Karavolias GK, Georgiadou P, Gkouziouta A, Kariofillis P, Karabela G, Tsiapras D, Sbarouni E, Chaidaroglou A, Degiannis D, Adamopoulos S, Voudris V.

Expert Opin Ther Targets. 2010 Dec;14(12):1283-9. doi: 10.1517/14728222.2010.523421. Epub 2010 Oct 20.

PMID:
20958219
2.

Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.

Vizza CD, Letizia C, Petramala L, Badagliacca R, Poscia R, Zepponi E, Crescenzi E, Nona A, Benedetti G, Ferrante F, Sciomer S, Fedele F.

Regul Pept. 2008 Nov 29;151(1-3):48-53. doi: 10.1016/j.regpep.2008.08.002. Epub 2008 Aug 16.

PMID:
18796317
3.

Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.

Launay D, Sitbon O, Le Pavec J, Savale L, Tchérakian C, Yaïci A, Achouh L, Parent F, Jais X, Simonneau G, Humbert M.

Rheumatology (Oxford). 2010 Mar;49(3):490-500. doi: 10.1093/rheumatology/kep398. Epub 2009 Dec 16.

PMID:
20015974
4.

Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.

Kemp K, Savale L, O'Callaghan DS, Jaïs X, Montani D, Humbert M, Simonneau G, Sitbon O.

J Heart Lung Transplant. 2012 Feb;31(2):150-8. doi: 10.1016/j.healun.2011.11.002. Epub 2011 Dec 3.

PMID:
22138355
5.

Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.

Sitbon O, Beghetti M, Petit J, Iserin L, Humbert M, Gressin V, Simonneau G.

Eur J Clin Invest. 2006 Sep;36 Suppl 3:25-31.

PMID:
16919007
6.

[Effects of long-term treatment with prostacyclin on plasma adrenomedullin in patients with primary pulmonary hypertension].

Nakayama T, Ishikita T, Matsuura H, Saji T.

J Cardiol. 2001 Nov;38(5):263-71. Japanese.

PMID:
11729726
7.

Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.

Johnson RF, Loyd JE, Mullican AL, Fink CA, Robbins IM.

J Heart Lung Transplant. 2007 Apr;26(4):363-9. Epub 2007 Mar 2.

PMID:
17403478
8.

Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension.

Leuchte HH, Holzapfel M, Baumgartner RA, Neurohr C, Vogeser M, Behr J.

Chest. 2005 Oct;128(4):2368-74.

PMID:
16236896
9.

Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.

Channick RN, Olschewski H, Seeger W, Staub T, Voswinckel R, Rubin LJ.

J Am Coll Cardiol. 2006 Oct 3;48(7):1433-7. Epub 2006 Sep 14.

11.

Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension.

Iannone F, Riccardi MT, Guiducci S, Bizzoca R, Cinelli M, Matucci-Cerinic M, Lapadula G.

Ann Rheum Dis. 2008 Aug;67(8):1121-6. Epub 2007 Nov 20.

12.

Clinical significance of plasma endothelin-1 level after bosentan administration in pulmonary arterial hypertension.

Hiramoto Y, Shioyama W, Higuchi K, Arita Y, Kuroda T, Sakata Y, Nakaoka Y, Fujio Y, Yamauchi-Takihara K.

J Cardiol. 2009 Jun;53(3):374-80. doi: 10.1016/j.jjcc.2009.01.002. Epub 2009 Feb 20.

13.

Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era.

Jacobs W, Boonstra A, Brand M, Rosenberg DM, Schaaf B, Postmus PE, Vonk Noordegraaf A.

J Heart Lung Transplant. 2010 Oct;29(10):1150-8. doi: 10.1016/j.healun.2010.05.011. Epub 2010 Jun 26.

PMID:
20580264
14.

Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan.

Benza RL, Rayburn BK, Tallaj JA, Pamboukian SV, Bourge RC.

Chest. 2008 Jul;134(1):139-45. doi: 10.1378/chest.07-2111. Epub 2008 Apr 10.

PMID:
18403673
15.

Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving bosentan therapy.

D'Alto M, Romeo E, Argiento P, Santoro G, Sarubbi B, Gaio G, Mélot C, Russo MG, Naeije R, Calabrò R.

Heart. 2010 Sep;96(18):1475-9. doi: 10.1136/hrt.2010.199661. Epub 2010 Jul 28.

PMID:
20668108
16.

Bosentan induces clinical and hemodynamic improvement in candidates for right-sided heart bypass surgery.

Hirono K, Yoshimura N, Taguchi M, Watanabe K, Nakamura T, Ichida F, Miyawaki T.

J Thorac Cardiovasc Surg. 2010 Aug;140(2):346-51. doi: 10.1016/j.jtcvs.2010.03.023.

17.

Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.

Jaïs X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, Hoeper MM, Lang IM, Mayer E, Pepke-Zaba J, Perchenet L, Morganti A, Simonneau G, Rubin LJ; Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group..

J Am Coll Cardiol. 2008 Dec 16;52(25):2127-34. doi: 10.1016/j.jacc.2008.08.059.

18.

Bosentan effects on hemodynamics and clinical outcome in heart failure patients with pulmonary hypertension awaiting cardiac transplantation.

Hefke T, Zittermann A, Fuchs U, Schulte-Eistrup S, Gummert JF, Schulz U.

Thorac Cardiovasc Surg. 2012 Feb;60(1):26-34. doi: 10.1055/s-0030-1250726. Epub 2011 Mar 22.

PMID:
21432755
19.

[Effects of bosentan in treatment of pulmonary arterial hypertension: a pilot study of 21 patients].

Jing ZC, Xu XQ, Ma CR, Wang Y, Wu Y, Jiang X, Pan L, Yang YJ.

Zhonghua Yi Xue Za Zhi. 2008 Aug 5;88(30):2136-9. Chinese.

PMID:
19080476
20.

[Impact of bosentan therapy on stress-induced pulmonary hypertension in patients with systemic sclerosis].

Volkov AV, Kurmukov IA, Iudkina NN, Glukhova SI, Nikolaeva EV.

Ter Arkh. 2015;87(1):49-56. Russian.

PMID:
25823269

Supplemental Content

Support Center